Polyethylene glycol
- Generic Name
- Polyethylene glycol
- Brand Names
- Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 25322-68-3
- Unique Ingredient Identifier
- 3WJQ0SDW1A
- Background
Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the...
- Indication
Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.
- Associated Conditions
- Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
- Associated Therapies
- Bowel preparation therapy, Eye lubrication
Second Bowel Preparation for Colonoscopy Failure
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT01510977
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Phase 3 Study of Sofosbuvir and Ribavirin
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 527
- Registration Number
- NCT01497366
- Locations
- 🇺🇸
Peter J. Ruane, M.D. Inc., Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Inc., Atlanta, Georgia, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
- Conditions
- Interventions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 2154
- Registration Number
- NCT01427296
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
- Conditions
- Interventions
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 248
- Registration Number
- NCT01384383
- Locations
- 🇺🇸
Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸North Shore University Hospital, Great Neck, New York, United States
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 332
- Registration Number
- NCT01329978
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Asheville Gastroenterology Associates, Asheville, North Carolina, United States
🇺🇸St. Louis University Gastroenterology and Hepatology Clinical Research, St. Louis, Missouri, United States
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
- Conditions
- Interventions
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 292
- Registration Number
- NCT01260350
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2010-10-28
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- Inje University
- Target Recruit Count
- 207
- Registration Number
- NCT01229800
- Locations
- 🇰🇷
Inje University School of Medicine, Haeundae Paik Hospital, Busan, Korea, Republic of
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 147
- Registration Number
- NCT01188772
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dr. Bruce Bacon, St. Louis, Missouri, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy
- Conditions
- Interventions
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2010-03-25
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT01093274
- Locations
- 🇮🇱
Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 64
- Registration Number
- NCT01054729
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Alamo Medical Research Center, San Antonio, Texas, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.